Literature DB >> 24568548

Adenovirus vector-induced CD8⁺ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection.

José Ronnie Vasconcelos1, Mariana R Dominguez, Ramon L Neves, Jonatan Ersching, Adriano Araújo, Luara I Santos, Fernando S Virgilio, Alexandre V Machado, Oscar Bruna-Romero, Ricardo T Gazzinelli, Mauricio M Rodrigues.   

Abstract

Heterologous prime-boost vaccination using plasmid DNA followed by replication-defective adenovirus vector generates a large number of specific CD8⁺ T effector memory (TEM) cells that provide long-term immunity against a variety of pathogens. In the present study, we initially characterized the frequency, phenotype, and function of these T cells in vaccinated mice that were subjected to infectious challenge with the human protozoan parasite Trypanosoma cruzi. We observed that the frequency of the specific CD8⁺ T cells in the spleens of the vaccinated mice increased after challenge. Specific TEM cells differentiated into cells with a KLRG1(High) CD27(Low) CD43(Low) CD183(Low)T-bet(High) Eomes(Low) phenotype and capable to produce simultaneously the antiparasitic mediators IFNγ and TNF. Using the gzmBCreERT2/ROSA26EYFP transgenic mouse line, in which the cells that express Granzyme B after immunization, are indelibly labeled with enhanced yellow fluorescent protein, we confirmed that CD8⁺ T cells present after challenge were indeed TEM cells that had been induced by vaccination. Subsequently, we observed that the in vivo increase in the frequency of the specific CD8⁺ T cells was not because of an anamnestic immune response. Most importantly, after challenge, the increase in the frequency of specific cells and the protective immunity they mediate were insensitive to treatment with the cytostatic toxic agent hydroxyurea. We have previously described that the administration of the drug FTY720, which reduces lymphocyte recirculation, severely impairs protective immunity, and our evidence supports the model that when large amounts of antigen-experienced CD8⁺ TEM cells are present after heterologous prime-boost vaccination, differentiation, and recirculation, rather than proliferation, are key for the resultant protective immunity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24568548      PMCID: PMC3997096          DOI: 10.1089/hum.2013.218

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  34 in total

Review 1.  Viral vectors as vaccine platforms: deployment in sight.

Authors:  Christine S Rollier; Arturo Reyes-Sandoval; Matthew G Cottingham; Katie Ewer; Adrian V S Hill
Journal:  Curr Opin Immunol       Date:  2011-04-20       Impact factor: 7.486

2.  Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.

Authors:  Stephanie A Freel; Laurie Lamoreaux; Pratip K Chattopadhyay; Kevin Saunders; David Zarkowsky; R Glenn Overman; Christina Ochsenbauer; Tara G Edmonds; John C Kappes; Coleen K Cunningham; Thomas N Denny; Kent J Weinhold; Guido Ferrari; Barton F Haynes; Richard A Koup; Barney S Graham; Mario Roederer; Georgia D Tomaras
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

3.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

Review 4.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

5.  Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Authors:  Richard A Koup; Mario Roederer; Laurie Lamoreaux; Jennifer Fischer; Laura Novik; Martha C Nason; Brenda D Larkin; Mary E Enama; Julie E Ledgerwood; Robert T Bailer; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

6.  Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.

Authors:  Joseph P Casazza; Kathryn A Bowman; Selorm Adzaku; Emily C Smith; Mary E Enama; Robert T Bailer; David A Price; Emma Gostick; Ingelise J Gordon; David R Ambrozak; Martha C Nason; Mario Roederer; Charla A Andrews; Frank M Maldarelli; Ann Wiegand; Mary F Kearney; Deborah Persaud; Carrie Ziemniak; Raphael Gottardo; Julie E Ledgerwood; Barney S Graham; Richard A Koup
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

Review 7.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

8.  Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.

Authors:  Filipe A Haolla; Carla Claser; Bruna C G de Alencar; Fanny Tzelepis; José Ronnie de Vasconcelos; Gabriel de Oliveira; Jaline C Silvério; Alexandre V Machado; Joseli Lannes-Vieira; Oscar Bruna-Romero; Ricardo T Gazzinelli; Ricardo Ribeiro dos Santos; Milena B P Soares; Mauricio M Rodrigues
Journal:  Vaccine       Date:  2009-07-25       Impact factor: 3.641

9.  Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine.

Authors:  José Ronnie Vasconcelos; Oscar Bruña-Romero; Adriano F Araújo; Mariana R Dominguez; Jonatan Ersching; Bruna C G de Alencar; Alexandre V Machado; Ricardo T Gazzinelli; Karina R Bortoluci; Gustavo P Amarante-Mendes; Marcela F Lopes; Mauricio M Rodrigues
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

10.  Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.

Authors:  Walter Jaoko; Etienne Karita; Kayitesi Kayitenkore; Gloria Omosa-Manyonyi; Susan Allen; Soe Than; Elizabeth M Adams; Barney S Graham; Richard A Koup; Robert T Bailer; Carol Smith; Len Dally; Bashir Farah; Omu Anzala; Claude M Muvunyi; Jean Bizimana; Tony Tarragona-Fiol; Philip J Bergin; Peter Hayes; Martin Ho; Kelley Loughran; Wendy Komaroff; Gwynneth Stevens; Helen Thomson; Mark J Boaz; Josephine H Cox; Claudia Schmidt; Jill Gilmour; Gary J Nabel; Patricia Fast; Job Bwayo
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

View more
  16 in total

1.  A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.

Authors:  Larissa H Haut; Amanda L Gill; Raj K Kurupati; Ang Bian; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Xiang Yang Zhou; Hildegund C J Ertl
Journal:  Hum Gene Ther Methods       Date:  2016-09-07       Impact factor: 2.396

Review 2.  Understanding CD8+ T Cell Immunity to Trypanosoma cruzi and How to Improve It.

Authors:  Eva V Acosta Rodríguez; Cintia L Araujo Furlan; Facundo Fiocca Vernengo; Carolina L Montes; Adriana Gruppi
Journal:  Trends Parasitol       Date:  2019-10-10

3.  Rapamycin Treatment Reduces Acute Myocarditis Induced by Trypanosoma cruzi Infection.

Authors:  Thabata L A Duque; Cynthia M Cascabulho; Gabriel M Oliveira; Andrea Henriques-Pons; Rubem F S Menna-Barreto
Journal:  J Innate Immun       Date:  2019-12-04       Impact factor: 7.349

Review 4.  Experimental Vaccines against Chagas Disease: A Journey through History.

Authors:  Olivia Rodríguez-Morales; Víctor Monteón-Padilla; Silvia C Carrillo-Sánchez; Martha Rios-Castro; Mariana Martínez-Cruz; Alejandro Carabarin-Lima; Minerva Arce-Fonseca
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

5.  Genetic vaccination against experimental infection with myotropic parasite strains of Trypanosoma cruzi.

Authors:  Adriano Fernando Araújo; Gabriel de Oliveira; Juliana Fraga Vasconcelos; Jonatan Ersching; Mariana Ribeiro Dominguez; José Ronnie Vasconcelos; Alexandre Vieira Machado; Ricardo Tostes Gazzinelli; Oscar Bruna-Romero; Milena Botelho Soares; Mauricio Martins Rodrigues
Journal:  Mediators Inflamm       Date:  2014-06-26       Impact factor: 4.711

6.  Unconventional Pro-inflammatory CD4+ T Cell Response in B Cell-Deficient Mice Infected with Trypanosoma cruzi.

Authors:  Melisa Gorosito Serrán; Jimena Tosello Boari; Facundo Fiocca Vernengo; Cristian G Beccaría; María C Ramello; Daniela A Bermejo; Amelia G Cook; Carola G Vinuesa; Carolina L Montes; Eva V Acosta Rodriguez; Adriana Gruppi
Journal:  Front Immunol       Date:  2017-11-21       Impact factor: 7.561

7.  Down Modulation of Host Immune Response by Amino Acid Repeats Present in a Trypanosoma cruzi Ribosomal Antigen.

Authors:  Carlos A Toro Acevedo; Bruna M Valente; Gabriela A Burle-Caldas; Bruno Galvão-Filho; Helton da C Santiago; Rosa M Esteves Arantes; Caroline Junqueira; Ricardo T Gazzinelli; Ester Roffê; Santuza M R Teixeira
Journal:  Front Microbiol       Date:  2017-11-10       Impact factor: 5.640

8.  Effects of IFN-γ coding plasmid supplementation in the immune response and protection elicited by Trypanosoma cruzi attenuated parasites.

Authors:  Cecilia Pérez Brandán; Andrea C Mesías; Cecilia Parodi; Rubén O Cimino; Carolina Pérez Brandán; Patricio Diosque; Miguel Ángel Basombrío
Journal:  BMC Infect Dis       Date:  2017-11-25       Impact factor: 3.090

9.  LFA-1 Mediates Cytotoxicity and Tissue Migration of Specific CD8+ T Cells after Heterologous Prime-Boost Vaccination against Trypanosoma cruzi Infection.

Authors:  Camila Pontes Ferreira; Leonardo Moro Cariste; Fernando Dos Santos Virgílio; Barbara Ferri Moraschi; Caroline Brandão Monteiro; Alexandre M Vieira Machado; Ricardo Tostes Gazzinelli; Oscar Bruna-Romero; Pedro Luiz Menin Ruiz; Daniel Araki Ribeiro; Joseli Lannes-Vieira; Marcela de Freitas Lopes; Mauricio Martins Rodrigues; José Ronnie Carvalho de Vasconcelos
Journal:  Front Immunol       Date:  2017-10-13       Impact factor: 7.561

Review 10.  CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development?

Authors:  Fernando Dos Santos Virgilio; Camila Pontes; Mariana Ribeiro Dominguez; Jonatan Ersching; Mauricio Martins Rodrigues; José Ronnie Vasconcelos
Journal:  Mediators Inflamm       Date:  2014-07-01       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.